1. Home
  2. EVN vs OMER Comparison

EVN vs OMER Comparison

Compare EVN & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EVN
  • OMER
  • Stock Information
  • Founded
  • EVN 1998
  • OMER 1994
  • Country
  • EVN United States
  • OMER United States
  • Employees
  • EVN N/A
  • OMER N/A
  • Industry
  • EVN Investment Bankers/Brokers/Service
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • EVN Finance
  • OMER Health Care
  • Exchange
  • EVN Nasdaq
  • OMER Nasdaq
  • Market Cap
  • EVN 441.5M
  • OMER 391.1M
  • IPO Year
  • EVN N/A
  • OMER 2009
  • Fundamental
  • Price
  • EVN $10.38
  • OMER $7.73
  • Analyst Decision
  • EVN
  • OMER Buy
  • Analyst Count
  • EVN 0
  • OMER 3
  • Target Price
  • EVN N/A
  • OMER $9.00
  • AVG Volume (30 Days)
  • EVN 101.2K
  • OMER 1.2M
  • Earning Date
  • EVN 01-01-0001
  • OMER 11-13-2024
  • Dividend Yield
  • EVN 4.78%
  • OMER N/A
  • EPS Growth
  • EVN N/A
  • OMER N/A
  • EPS
  • EVN 0.34
  • OMER N/A
  • Revenue
  • EVN N/A
  • OMER N/A
  • Revenue This Year
  • EVN N/A
  • OMER N/A
  • Revenue Next Year
  • EVN N/A
  • OMER N/A
  • P/E Ratio
  • EVN $29.94
  • OMER N/A
  • Revenue Growth
  • EVN N/A
  • OMER N/A
  • 52 Week Low
  • EVN $8.64
  • OMER $1.81
  • 52 Week High
  • EVN $10.45
  • OMER $7.51
  • Technical
  • Relative Strength Index (RSI)
  • EVN 37.22
  • OMER 77.09
  • Support Level
  • EVN $10.40
  • OMER $5.55
  • Resistance Level
  • EVN $10.60
  • OMER $7.51
  • Average True Range (ATR)
  • EVN 0.10
  • OMER 0.64
  • MACD
  • EVN 0.01
  • OMER 0.27
  • Stochastic Oscillator
  • EVN 21.43
  • OMER 96.88

About EVN Eaton Vance Municipal Income Trust

Eaton Vance Municipal Income Trust is a United States-based diversified, closed-end management investment company. Its investment objective is to provide current income exempt from regular federal income tax. The trust's portfolio of investments majorly consists of debt instruments of governments, municipal organizations the interest on which is exempt from regular federal income tax and has also some exposure to corporate bonds and other instruments.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: